Clinical Trials for Refractory Acute Lymphoblastic Leukemia

Find clinical trials for refractory acute lymphoblastic leukemia. Discover research opportunities and treatment options in your area.

19 Active Trials Found

Showing 19 trials on this page

Page 1 of 1

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT ID: NCT03326921

This clinical trial is testing a new type of immunotherapy called HA-1 T cell therapy to treat patients with certain types of acute leukemia that have come back, are not responding to treatment, or...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT ID: NCT03128034

This clinical trial is looking at a new treatment called 211^astatine-BC8-B10 for patients with certain types of blood cancers, including high-risk acute myeloid leukemia (AML), acute lymphoblastic...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT ID: NCT05761171

This clinical trial is exploring a new treatment for young children with certain types of leukemia that have either come back after previous treatment (relapsed) or did not respond to treatment (re...

Recruiting

Phase: PHASE2 Type: interventional Locations: Philadelphia, Pennsylvania, United States, Buffalo, New York, United States +83 more

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

NCT ID: NCT03263572

This clinical trial is studying a combination of four medications—blinatumomab, methotrexate, cytarabine, and ponatinib—to see how well they work for patients with Philadelphia chromosome-positive ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Houston, Texas, United States

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT ID: NCT03670966

This clinical trial is studying a new treatment approach for patients with high-risk acute leukemia or myelodysplastic syndrome, especially those whose disease has come back or is not responding to...

Recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

NCT ID: NCT06847269

This clinical trial, called CAR19PK, is studying a new treatment for young patients (up to 21 years old) with a type of leukemia called CD19-positive leukemia, which can be difficult to treat when ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Memphis, Tennessee, United States

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

NCT ID: NCT06287528

This clinical trial is studying a new type of treatment called CAR T-cell therapy, specifically using a modified version called 19-28z/IL-18, for patients with acute lymphoblastic leukemia (ALL). T...

Recruiting

Phase: PHASE1 Type: interventional Locations: New York, New York, United States, Middletown, New Jersey, United States +5 more

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

NCT ID: NCT05418088

This clinical trial is studying a new treatment for certain types of blood cancers, specifically targeting those that have come back or have not responded to previous treatments. The treatment invo...

Recruiting

Phase: PHASE1 Type: interventional Locations: Columbus, Ohio, United States, Columbus, Ohio, United States

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies

NCT ID: NCT06316427

This clinical trial is investigating a new treatment for patients with a type of leukemia called T-cell acute lymphoblastic leukemia (T-ALL) or lymphoma that has not responded to standard therapies...

Recruiting

Phase: PHASE1 Type: interventional Locations: Chengdu, Sichuan, China, Beijing, Beijing, China +2 more

Personalized NK Cell Therapy in CBT

NCT ID: NCT02727803

This clinical trial is looking at a new treatment called personalized natural killer (NK) cell therapy for patients with certain types of blood cancers, including leukemia, lymphoma, and myelodyspl...

Recruiting

Phase: PHASE2 Type: interventional Locations: Houston, Texas, United States

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

NCT ID: NCT02392572

This clinical trial is studying a new treatment called ONC201 for patients with certain types of leukemia or high-risk myelodysplastic syndrome (a blood disorder) that have either returned after tr...

Recruiting

Phase: PHASE1 Type: interventional Locations: Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

NCT ID: NCT03136146

This clinical trial is studying a combination of chemotherapy drugs to see how well they work for patients with certain types of blood cancers, including acute lymphoblastic leukemia (ALL), lymphob...

Recruiting

Phase: PHASE2 Type: interventional Locations: Houston, Texas, United States

Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia

NCT ID: NCT06581081

This clinical trial is exploring a new approach to treating relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) using a targeted therapy called CD19 CAR-T cell therapy. The study aim...

Recruiting

Phase: NA Type: interventional Locations: Beijing, Beijing, China

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects with Relapsed or Refractory T-cell Malignancies

NCT ID: NCT06316856

This clinical trial is studying a new type of treatment called CD5 Chimeric Antigen Receptor (CAR) T cell therapy for patients with a type of cancer known as relapsed or refractory T-cell acute lym...

Recruiting

Phase: PHASE1 Type: interventional Locations: Chengdu, Sichuan, China, Beijing, Beijing, China +2 more

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

NCT ID: NCT04996160

This clinical trial, called RELPALL2, is studying a medication called palbociclib when used alongside chemotherapy for children and young adults with a type of blood cancer known as acute lymphobla...

Recruiting

Phase: PHASE1 Type: interventional Locations: Stanford, California, United States

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

NCT ID: NCT06447987

This clinical trial is studying a new treatment called CAR T-cell therapy for adults with a type of blood cancer known as CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has either ret...

Recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

NCT ID: NCT06641024

This clinical trial is studying a new treatment option for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The researchers want to see if a s...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Shanghai, , China

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

NCT ID: NCT05334823

This clinical trial is studying a new treatment called pCAR-19B for children and teenagers with a type of blood cancer known as B-cell acute lymphoblastic leukemia (B-ALL) that has come back or did...

Recruiting

Phase: PHASE2 Type: interventional Locations: Nanchang, , China, Nanchang, Jiangxi, China +9 more

ThisCART19A Bridging to alloHSCT for R/R B-ALL

NCT ID: NCT05679687

This clinical trial, called ThisCART19A, is studying a new treatment for adults with a type of blood cancer known as refractory or relapsed B-cell acute lymphoblastic leukemia (B-ALL). The goal is ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Suzhou, Jiangsu, China

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions